P. Phillips

发表

Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial

J. Desai, K. Gelmon, J. Hunt, 2017 .

Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.

F. Meric-Bernstam, F. Janku, A. Naing, 2021, The oncologist.

Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.

F. Meric-Bernstam, F. Janku, A. Naing, 2020, The oncologist.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer

R. Greil, J. Baselga, H. Rugo, 2008 .

Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.

M. Carleton, Z. Wainberg, S. Piha-Paul, 2018 .

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Hongyu Zhao, M. Carleton, K. Schalper, 2020, Nature Medicine.

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2020 .

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

R. Greil, J. Baselga, H. Lane, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

D. Osoba, J. Olson, M. Prados, 2000, British Journal of Cancer.

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

H. Kantarjian, J. Cortes, R. Stone, 2004 .

H. Kantarjian, J. Cortes, R. Stone, 2006 .

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Michael Thomas, Melissa L. Johnson, K. Yoh, 2021 .

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience

F. Meric-Bernstam, Y. Yamamura, V. Subbiah, 2022, Journal of the advanced practitioner in oncology.

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

H. Kantarjian, S. Verstovsek, A. Roberts, 2013 .

BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

J. Desai, K. Gelmon, G. Curigliano, 2018 .

A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy

C. Rudin, L. Krug, P. Fracasso, 2016 .

A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).

T. Seufferlein, Z. Wainberg, J. Bendell, 2019, Journal of Clinical Oncology.

Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.

A. Korman, A. Nagrial, L. Siu, 2017 .

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

M. Carleton, E. Jaffee, C. Drake, 2018 .

P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

R. Heist, K. Yoh, A. Spira, 2021, Journal of Thoracic Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Hongyu Zhao, M. Carleton, K. Schalper, 2020, Nature Medicine.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

A. Tolcher, R. Heist, F. Meric-Bernstam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

R. Heist, F. Meric-Bernstam, K. Yoh, 2021 .